Monte Rosa Therapeutics (GLUE) Other Accumulated Expenses (2020 - 2025)

Monte Rosa Therapeutics' Other Accumulated Expenses history runs 6 years deep, the most recent figure standing at $4.4 million for Q1 2025.

• In Q1 2025, Other Accumulated Expenses rose 104.68% year-over-year to $4.4 million; the TTM figure through Mar 2025 stood at $4.4 million (up 104.68% YoY), while the FY2024 annual figure was $3.4 million, up 100.72% from the prior year.
• Other Accumulated Expenses for Q1 2025 stood at $4.4 million, up from $3.4 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $5.0 million in Q4 2022, with the low at $840000.0 in Q4 2021.
• The 5-year median for Other Accumulated Expenses is $2.5 million (2023), against an average of $2.7 million.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses soared 497.62% in 2022, then sank 66.71% in 2023.
• Monte Rosa Therapeutics' Other Accumulated Expenses stood at $840000.0 in 2021, then jumped by 497.62% to $5.0 million in 2022, then tumbled by 66.71% to $1.7 million in 2023, then jumped by 100.72% to $3.4 million in 2024, then soared by 31.81% to $4.4 million in 2025.
• Business Quant data shows GLUE's Other Accumulated Expenses at $4.4 million in Q1 2025, $3.4 million in Q4 2024, and $1.3 million in Q3 2024.